Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs) EQUITY
$111.20
pos +0.66
+0.60%
Today's Range: 110.74 - 112.95 | GILD Avg Daily Volume: 10,763,800
Last Update: 07/28/15 - 11:34 AM EDT
Volume: 4,476,909
YTD Performance: 17.27%
Open: $112.52
Previous Close: $110.54
52 Week Range: $85.95 - $123.37
Oustanding Shares: 1,469,605,980
Market Cap: 165,815,642,723
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 11 10 11
Moderate Buy 3 3 3 3
Hold 1 1 2 2
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
Mean Rec. 1.50 1.47 1.59 1.56
Latest Dividend: 0.43
Latest Dividend Yield: 1.52%
Dividend Ex-Date: 06/12/15
Price Earnings Ratio: 12.85
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
12.85 12.80 28.18
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
7.38% 23.04% 298.34%
GROWTH 12 Mo 3 Yr CAGR
Revenue 122.20 1.97 0.43
Net Income 294.40 3.32 0.62
EPS 305.00 3.39 0.63
Earnings for GILD:
EBITDA 16.32B
Revenue 24.89B
Average Earnings Estimates
Qtr (06/15) Qtr (09/15) FY (12/15) FY (12/16)
Average Estimate $2.83 $2.72 $11.04 $9.56
Number of Analysts 1 1 1 1
High Estimate $2.83 $2.72 $11.04 $9.56
Low Estimate $2.83 $2.72 $11.04 $9.56
Prior Year $2.32 $1.79 $7.91 $11.04
Growth Rate (Year over Year) 21.98% 51.96% 39.57% -13.41%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Competition and lower earnings cloud its future.

Tread Carefully in the Market Real Money Pro($)

This week could easily bring additional selling.
Two tech companies in Jim Cramer's charitable trust report as well.
Biogen's weak numbers leave biotechs ailing.
How Netflix, Tesla and Amazon are helping this market grind higher.
The fearsome foursome have been reborn.

Flat Start, but Celgene Shines Real Money Pro($)

The market opens flat as we try for five days in a row of gains for first time in 2015. Celgene (CELG) has a strong start as several analysts raise price targets after its announcement of the planned acquisition of Receptos (RCPT) and the company raising its earnings-per-share guidance the other day. Let the speculation begin about what biotech juggernaut Gilead Sciences (GILD) might buy with its ever-increasing free cash flow.

Columnist Conversations

DuPont had a particularly poor earnings release, outlook and conference call today. As we have previously dis...
ETP
Looks like the margin call on that big mlp fund is done!
Same question put differently; why buy ahead of the Fed tomorrow?
Regarding weak markets; isn't this what you want to see ahead of the Fed tomorrow? Runaway markets will have...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.